RNLXY
Renalytix plcCompany with tickers: RNLXY, RENXF
CIK
1811115
CUSIP
75973T200
Shares Outstanding
331,206,012
Website
https://www.renalytix.com
Investor Relations
https://investors.renalytix.com/
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $522,000 | USD | 2024-09-30 | 10-Q | 2024-11-19 |
| Revenue (ASC 606) | $500,000 | USD | 2024-09-30 | 10-Q | 2024-11-19 |
| Cost of Revenue | $422,000 | USD | 2024-09-30 | 10-Q | 2024-11-19 |
| Gross Profit | $100,000 | USD | 2024-09-30 | 10-Q | 2024-11-19 |
| Operating Expenses | $4,192,000 | USD | 2024-09-30 | 10-Q | 2024-11-19 |
| Research & Development | — | ||||
| Operating Income | $-4,093,000 | USD | 2024-09-30 | 10-Q | 2024-11-19 |
| Net Income | $-4,728,000 | USD | 2024-09-30 | 10-Q | 2024-11-19 |
| EPS (Basic) | $-0.04 | USD/shares | 2024-09-30 | 10-Q | 2024-11-19 |
| EPS (Diluted) | $-0.04 | USD/shares | 2024-09-30 | 10-Q | 2024-11-19 |